My only other point was the press release cited was not very credible in its research and appears to be from a paid content creation team that publicizes dozens of paid press releases a month. What business of yours is it if I am a trader. There is nothing to trade here. I do not believe in the Pharma Tech company, why would I or anyone? With all due respect, Pharma Tech is underfunded, does not appear to have an infrastructure or a regional or national sales force. Most businesses whether public or private fail as a result of not having enough capital and or poor planning. Is it Suzy Q shareholders fault Pharma Tech financial resources appear worse than the average household in middle America? Add that it is very difficult to penetrate a mature, competitive market with new technologies on the horizon and cheaper overseas devices. This is one of the dozens of FU gambling plays I make. No different than putting chips on various numbers on a roulette table. As far as bets go, I had this at 50/50 based only on a competent law firm suing a Bad Actor that has had mediocre results at best in prior high ticket litigation actions against them. Any expectation of a near 9 figure win has evaporated, but the Fat Lady has not finished singing. While the odds are low I have been known to be lucky at times. Other than the slim potential of a court victory nothing excites me about the growth or revenue prospects here. To your point, even if there was transparency, this is not worth modeling. There is a reason that private equity, friends and family and even the suppliers are not providing funding. After all, it would be mutually beneficial for the suppliers to fund this enterprise. Cheap money is flowing like a river from Wall Street to Main Street, so either I am missing something or there is a lack of transparency. I do not wish to communicate with you further, so please refrain from any further private communique. You didn't even upset my appetite for lunch if that was your intention.
My two points were very straightforward. I do not
My only other point was the press release cited was not very credible in its research and appears to be from a paid content creation team that publicizes dozens of paid press releases a month. What business of yours is it if I am a trader. There is nothing to trade here. I do not believe in the Pharma Tech company, why would I or anyone? With all due respect, Pharma Tech is underfunded, does not appear to have an infrastructure or a regional or national sales force. Most businesses whether public or private fail as a result of not having enough capital and or poor planning. Is it Suzy Q shareholders fault Pharma Tech financial resources appear worse than the average household in middle America? Add that it is very difficult to penetrate a mature, competitive market with new technologies on the horizon and cheaper overseas devices. This is one of the dozens of FU gambling plays I make. No different than putting chips on various numbers on a roulette table. As far as bets go, I had this at 50/50 based only on a competent law firm suing a Bad Actor that has had mediocre results at best in prior high ticket litigation actions against them. Any expectation of a near 9 figure win has evaporated, but the Fat Lady has not finished singing. While the odds are low I have been known to be lucky at times. Other than the slim potential of a court victory nothing excites me about the growth or revenue prospects here. To your point, even if there was transparency, this is not worth modeling. There is a reason that private equity, friends and family and even the suppliers are not providing funding. After all, it would be mutually beneficial for the suppliers to fund this enterprise. Cheap money is flowing like a river from Wall Street to Main Street, so either I am missing something or there is a lack of transparency. I do not wish to communicate with you further, so please refrain from any further private communique. You didn't even upset my appetite for lunch if that was your intention.
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Gnosis Lab's Grand Re-Opening: A New Era for Diagnostics
Gnosis Lab Grand Re-Opening Celebration Gnosis, a modern diagnostic laboratory previously known as Mountain View Medical Laboratory, is excited to announce its grand re-opening at its flagship location. This event signifies a crucial transition for the lab as it seeks to blend years of reliable community service with a fresh identity and enhanced capabilities. Commitment...
Continue Reading
New Propane Contract Boosts Titan NRG (TTNN) Growth
Titan NRG, Inc. Announces Major Propane Contract Secured Titan NRG, Inc. (OTC: TTNN) has a big contract for the 150,000 gallons of propane supply. Given to one of its subsidiaries, this contract represents a significant turning point for the business. Under this contract, propane will be delivered over the next year to a southern Arizona reservation. Crucially in securing...
Continue Reading
Bitcoin Price Decline: Impact of DOJ and Economic Conditions
Bitcoin Price Experiences a Notable Decline Bitcoin has recently faced a serious downturn, falling to around $93,925 as fears surrounding U.S. interest rate changes and potential government sales of Bitcoin emerged. This has created a concerning environment for cryptocurrency investors, highlighting the volatility of digital assets. Market Sentiment and Economic Shifts...
Continue Reading
Cogitate and One Inc Team Up to Revolutionize Payments
Cogitate Partners with One Inc to Transform Digital Payments -Customers Enjoy a Seamless Experience by Unifying All Payment Flows into One Comprehensive Platform- Cogitate, a provider of cloud-native core policy, billing, and claims applications for insurers, is excited to announce its partnership with One Inc, the leading digital payments network specifically for the...
Continue Reading
Alnylam Pharmaceuticals Achieves New Stock Milestone of $287.88
Alnylam Pharmaceuticals Reaches Record Stock Price Alnylam Pharmaceuticals Inc. has recently made headlines after its stock price reached a remarkable all-time high of $287.88. This surge demonstrates a substantial increase in investor confidence, bolstered by an impressive 1-year change of 71.84% in the company's stock. Known for its groundbreaking work in RNA...
Continue Reading